MA50798A - Procédés d'utilisation et compositions contenant du dulaglutide - Google Patents

Procédés d'utilisation et compositions contenant du dulaglutide

Info

Publication number
MA50798A
MA50798A MA050798A MA50798A MA50798A MA 50798 A MA50798 A MA 50798A MA 050798 A MA050798 A MA 050798A MA 50798 A MA50798 A MA 50798A MA 50798 A MA50798 A MA 50798A
Authority
MA
Morocco
Prior art keywords
methods
compositions containing
dulaglutide
containing dulaglutide
compositions
Prior art date
Application number
MA050798A
Other languages
English (en)
French (fr)
Inventor
David Andrew Cox
Zvonko Milicevic
Lai San Tham
Andrew Gordon Werner
David Bradley Woodward
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64572530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50798(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA50798A publication Critical patent/MA50798A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
MA050798A 2017-11-21 2018-11-13 Procédés d'utilisation et compositions contenant du dulaglutide MA50798A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762589244P 2017-11-21 2017-11-21

Publications (1)

Publication Number Publication Date
MA50798A true MA50798A (fr) 2020-09-30

Family

ID=64572530

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050798A MA50798A (fr) 2017-11-21 2018-11-13 Procédés d'utilisation et compositions contenant du dulaglutide

Country Status (21)

Country Link
US (2) US11576950B2 (https=)
EP (1) EP3713593A2 (https=)
JP (3) JP7221956B2 (https=)
KR (2) KR102589234B1 (https=)
CN (2) CN120478602A (https=)
AU (2) AU2018372709B2 (https=)
BR (1) BR112020007817A2 (https=)
CL (1) CL2020001252A1 (https=)
CR (1) CR20200202A (https=)
DO (1) DOP2020000104A (https=)
EA (1) EA202090971A1 (https=)
EC (1) ECSP20026436A (https=)
IL (1) IL274563B2 (https=)
JO (1) JOP20200126B1 (https=)
MA (1) MA50798A (https=)
MX (1) MX2020005231A (https=)
PE (1) PE20200847A1 (https=)
PH (1) PH12020550795A1 (https=)
SG (1) SG11202003687RA (https=)
UA (1) UA127588C2 (https=)
WO (1) WO2019103875A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020190591A1 (en) * 2019-03-15 2020-09-24 Eli Lilly And Company Preserved formulations
KR20220132606A (ko) * 2020-01-30 2022-09-30 일라이 릴리 앤드 캄파니 둘라글루티드의 치료 용도
EP4153130A1 (en) * 2020-05-19 2023-03-29 F. Hoffmann-La Roche AG The use of chelators for the prevention of visible particle formation in parenteral protein solutions
CA3223313A1 (en) 2021-06-23 2022-12-29 Eli Lilly And Company Methods of using and compositions including an incretin analog

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
DK1831252T3 (da) 2004-12-22 2009-10-05 Lilly Co Eli GLP-1 analog fusionsproteinformuleringer
ATE499088T1 (de) * 2007-07-10 2011-03-15 Lilly Co Eli Glp-1-fc fusionsprotein-formulierung
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
WO2016168388A2 (en) * 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
CA3065295C (en) 2017-06-01 2023-08-29 Eli Lilly And Company Dulaglutide for the treatment of chronic kidney disease

Also Published As

Publication number Publication date
BR112020007817A2 (pt) 2020-10-06
JP2024056908A (ja) 2024-04-23
US20200330558A1 (en) 2020-10-22
ECSP20026436A (es) 2020-06-30
NZ763815A (en) 2023-11-24
EP3713593A2 (en) 2020-09-30
JP7221956B2 (ja) 2023-02-14
DOP2020000104A (es) 2020-08-31
JOP20200126B1 (ar) 2024-04-18
KR20220146656A (ko) 2022-11-01
IL274563B1 (en) 2023-08-01
KR102589234B1 (ko) 2023-10-16
CL2020001252A1 (es) 2020-10-30
AU2022203372A1 (en) 2022-06-09
AU2022203372B2 (en) 2025-04-10
MX2020005231A (es) 2020-08-24
IL274563A (en) 2020-06-30
KR20200076705A (ko) 2020-06-29
WO2019103875A2 (en) 2019-05-31
JOP20200126A1 (ar) 2020-05-21
EA202090971A1 (ru) 2020-08-07
UA127588C2 (uk) 2023-10-25
JP2021502379A (ja) 2021-01-28
WO2019103875A3 (en) 2019-07-25
PH12020550795A1 (en) 2021-04-19
CN120478602A (zh) 2025-08-15
CA3082625A1 (en) 2019-05-31
JP2022062153A (ja) 2022-04-19
IL274563B2 (en) 2023-12-01
JP7818412B2 (ja) 2026-02-20
US20240189394A1 (en) 2024-06-13
AU2018372709B2 (en) 2022-04-28
CR20200202A (es) 2020-08-20
AU2018372709A1 (en) 2020-05-14
SG11202003687RA (en) 2020-06-29
CN111356472A (zh) 2020-06-30
PE20200847A1 (es) 2020-08-18
US11576950B2 (en) 2023-02-14

Similar Documents

Publication Publication Date Title
EP3704239A4 (en) CASZ COMPOSITIONS AND METHOD OF USE
EP3277698A4 (en) SI-CONTAINING FILM-FORMING COMPOSITIONS AND METHOD FOR USE THEREOF
EP3634430A4 (en) MULTIBIOTICS AND METHOD OF USING THEREFORE
EP3790596A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE
EP3775203A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
EP3703806A4 (en) HEMOSTASIS DEVICES AND METHOD OF USE
EP3890736A4 (en) HELIOS SMALL MOLECULE DEGRADERS AND METHOD OF USE
EP3630199A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THEIR USE
EP3630788A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THEIR USE
EP3630789A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THEIR USE
EP3612198A4 (en) GENETICALLY PRODUCED COMMENSAL BACTERIA AND METHODS OF USE
EP3402493A4 (en) NEURAL ORGANOID COMPOSITION AND METHOD OF USE
EP3435956A4 (en) Photo-stabilized compositions and methods of use
EP3452597A4 (en) METHODS AND COMPOSITIONS FROM BIOLOGICALLY ACTIVE SUBSTANCES
EP3303634A4 (en) CAS9 VARIANTS AND METHOD FOR USE THEREOF
EP3893917A4 (en) IL-15 COMPOSITIONS AND METHODS OF USE THEREOF
EP3487379A4 (en) MEDICAL DEVICE AND METHOD FOR USE
EP3635000A4 (en) Manabodies and methods of using
EP3313404A4 (en) THERAPEUTIC COMPOSITIONS, COMBINATIONS AND METHODS OF USE
EP3352774A4 (en) FLAVONOID COMPOSITIONS AND METHODS OF USE
EP3414321A4 (en) VCN CONVEYOR COMPOSITIONS AND METHOD FOR USE THEREOF
MA48797A (fr) Variants de l'endonucléase cblb , compositions et procédés d'utilisation
EP3490569A4 (en) TOPICAL COMPOSITIONS AND METHODS FOR USE THEREOF
EP3478277A4 (en) ANTI-ACNE COMPOSITIONS AND METHOD FOR USE
EP3386927A4 (en) POLYMERIC COMPOSITIONS AND METHODS OF USE